Clinical Trials

1,000 enrolled

Breast Neoplasms

NCT05238922 2026-04-14

Study of INCB123667 in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologic

604 enrolled

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Digestive System Neoplasms

NCT05358249 2026-04-14

KontRASt-03

Phase 1/2 Active not recruiting

74 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05827081 2026-04-14

Adjuvant WIDER

1,400 enrolled

Breast Neoplasms, Breast Neoplasms, Male

NCT06380751 2026-04-14

EvoPAR-BR01

500 enrolled

Advanced Breast Cancer

NCT04802759 2026-04-13

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

316 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT05038631 2026-04-13

Managed Access Programs for LEE011, Ribociclib

Available

Breast Neoplasms

NCT06625775 2026-04-13

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

BreastGastrointestinalThoracic

392 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT06188520 2026-04-08

CYCAD-1

564 enrolled

BreastGynecologic

ER+ HER2- Advanced Breast Cancer

NCT05203172 2026-04-07

The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials

Phase 4 Recruiting

46 enrolled

Other solid neoplasm

Solid Tumors

NCT06065748 2026-04-06

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

1,050 enrolled

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

NCT07405801 2026-04-06

A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer

Phase 2 Recruiting

80 enrolled

Phase 4 Active not recruiting

Breast Neoplasms

NCT05161195 2026-04-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07340658 2026-04-02

SIE-3

300 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT01872260 2026-04-01

Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer

255 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT03701334 2026-04-01

NATALEE

5,101 enrolled 5 FDA

Breast Neoplasms

NCT04943497 2026-04-01

PROSPERITY

Completed

2,424 enrolled

Breast Neoplasms

NCT06830720 2026-04-01

CAROLEEN

3,250 enrolled

Breast Neoplasms

NCT06905301 2026-04-01

IMPULSE

240 enrolled

Breast Neoplasms

NCT07054190 2026-03-31

A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer

Phase 2 Recruiting

60 enrolled

Breast Neoplasms

NCT06726148 2026-03-27

Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

280 enrolled

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07492641 2026-03-25

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

1,056 enrolled

HR+/HER2- Breast Cancer

NCT07174336 2026-03-20

A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)

920 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03424005 2026-03-16

Morpheus-panBC

792 enrolled

Breast Neoplasms

NCT05697146 2026-03-16

RosaLEE

Active not recruiting

1,019 enrolled

Breast Neoplasms

NCT06930859 2026-03-16

ELEGANCE

2,766 enrolled

Phase 2 Active not recruiting

Breast Neoplasms

NCT04417621 2026-03-12

Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

134 enrolled

Dermatologic

Melanoma

NCT04862663 2026-03-12

CAPItello-292

895 enrolled

Phase 1/2 Active not recruiting

Locally Advanced (Inoperable) or Metastatic Breast Cancer

NCT05573555 2026-03-09

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

20 enrolled

Breast Neoplasms

NCT05768139 2026-03-02

PIKALO-1

BreastGynecologicHead & Neck

720 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Diseases, Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Neoplasms, Neoplasms by Site, Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms, Endometrial Neoplasms

NCT06760637 2026-03-02

FourLight-3

1,020 enrolled

Unilateral Breast Neoplasms, Breast Neoplasms, Recurrence

NCT06757634 2026-02-05

Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)

674 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT06797531 2026-02-04

NISLEESA

177 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03616587 2026-01-28

SERENA-1

396 enrolled

Phase 1 Active not recruiting

Breast Neoplasms

NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

105 enrolled

Thoracic

EGFR-mutant Non-small Cell Lung Cancer

NCT04964934 2026-01-16

SERENA-6

Phase 3 Active not recruiting

315 enrolled

Breast Diseases, Breast Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site

NCT07002177 2026-01-07

A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC

196 enrolled

Breast Neoplasms

NCT05563220 2026-01-06

ELEVATE

435 enrolled

Breast Neoplasms

NCT06148506 2025-12-05

ValerEE

Active not recruiting

376 enrolled

GastrointestinalGynecologicSarcoma

HR+HER2- Advanced Breast Cancer

NCT05252416 2025-11-28

(VELA) Study of BLU-222 in Advanced Solid Tumors

Phase 1 Terminated

50 enrolled

Adenocarcinoma Of Esophagus, Carcinosarcoma, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT06495164 2025-11-25

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer

Active not recruiting

1 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

Phase 2 Completed

327 enrolled

Breast Neoplasms

NCT05508906 2025-10-22

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

190 enrolled

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

Phase 2 Completed

376 enrolled 17 charts

GastrointestinalHead & NeckSarcomaThoracic

Breast Neoplasms

NCT05429502 2025-10-10

Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Phase 1 Terminated

12 enrolled

CNSSarcoma

Glioma, Medulloblastoma, Neuroblastoma, Recurrence, Rhabdomyosarcoma

NCT04000529 2025-09-30

Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies

Phase 1 Terminated

122 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

NCT05216432 2025-09-22

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

930 enrolled

Breast Neoplasms

NCT06239467 2025-09-09

PIKture-01

200 enrolled